Genmab — Marts 2018
-
meanwhile the 'MASTER' study now started recruiting - KRdD -
https://clinicaltrials.gov/ct2/show/results/NCT03224507?term=NCT03224507&rank=1 -
Ser dog ud til PE værdien er ved at være lidt anstrengt p.g.a faldende USD. Vi skal forvente en fladende PE fremadrettet og for 2015,16,17 havde vi PE på 73, 61 57,9 i.f.m årsregnskab og p.t ligger vi på 57 så meget mere kan PE vel ikke trække med mindre der kommer noget uventet positivt a la positiv solid data eller lignende eller evt. opjustering af Dara salg over de 2.3mia
-
I princippet ja - men også afhængig af hvor gode Genmab har været til at hedge mod valutaudsving. Derudover kan evt. prisstigninger komme på banen som kan opveje en evt. svag USD. Men min pointe er nu mere at PE vil/bør falde fremadrettet i takt med Darzalex salget nærmer sig peak salg, så 5 point ned per år fremadretter skal vi nok forvente.
-
-
Lidt mere om Bluebird og relapsed myeloma patienter: “I think that CAR T cell therapy is very promising and exciting. It is still early, however, and much research to be done. I have personally treated three patients with far advanced refractory myeloma on CAR T cell protocols — two patients on distinct BCMA protocols and one patient on CD19 protocol. All patients responded and benefitted. However, with time, the myeloma has returned,” Anderson said in a statement provided to STAT by Dana-Farber
-
Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer - https://clinicaltrials.gov/ct2/show/study/NCT03473730?term=cancer&lupd_s=03%2F08%2F2018&lupd_d=14
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind